Catalyst Pharmaceuticals Beats Q4 Estimates, Issues Strong 2026 Revenue Guidance

Catalyst Pharmaceuticals (CPRX) reported fourth-quarter financial results that exceeded analyst expectations, driven by robust commercial performance across its product line. The company's core products, Firdapse and Agamree, recorded significant year-over-year sales growth, reflecting strong market demand and successful uptake. Following these strong results, management issued upbeat revenue guidance for the fiscal year 2026, signaling confidence in its long-term trajectory. Analysts attribute this success to the company's effective commercial strategy within the rare disease sector. The earnings beat underscores Catalyst's operational efficiency and its ability to scale its pharmaceutical portfolio effectively. Investor sentiment remains positive as the company continues to demonstrate sustainable revenue growth and market leadership.